{"id":649269,"date":"2023-04-26T19:28:01","date_gmt":"2023-04-26T19:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=649269"},"modified":"2023-04-26T19:28:01","modified_gmt":"2023-04-26T19:28:01","slug":"bronchopulmonary-dysplasia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examine-delveinsight-key-companies-oak-hill-bio-advent-therapeutics-inc-airway-therapeutic","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bronchopulmonary-dysplasia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examine-delveinsight-key-companies-oak-hill-bio-advent-therapeutics-inc-airway-therapeutic_649269.html","title":{"rendered":"Bronchopulmonary Dysplasia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies &#8211; Oak Hill Bio, Advent Therapeutics Inc, Airway Therapeutic"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1682510440.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bronchopulmonary Dysplasia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - Oak Hill Bio, Advent Therapeutics Inc, Airway Therapeutic\" src=\"https:\/\/www.abnewswire.com\/uploads\/1682510440.jpeg\" alt=\"Bronchopulmonary Dysplasia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - Oak Hill Bio, Advent Therapeutics Inc, Airway Therapeutic\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cBronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Bronchopulmonary Dysplasia.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology as well as the Bronchopulmonary Dysplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Bronchopulmonary Dysplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bronchopulmonary-dysplasia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Bronchopulmonary Dysplasia Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Bronchopulmonary Dysplasia Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Bronchopulmonary Dysplasia market size was valued approximately <strong>USD 0.28 Million<\/strong> in 2021 and is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period<strong> (2019-2032)<\/strong><\/li>\n<li>The total incident cases of Bronchopulmonary Dysplasia in the 7MM was found to be approximately <strong>17,058 cases<\/strong> in 2021. These cases are expected to increase by 2032<\/li>\n<li>Among 7MM, the United States had the highest incident cases of Bronchopulmonary Dysplasia with approximately <strong>13,222 cases<\/strong> in 2021<\/li>\n<li>Among EU4 and the UK, Germany had the highest incident population of Bronchopulmonary Dysplasia with <strong>944 cases<\/strong>, followed by France with <strong>931 cases<\/strong> in 2021. On the other hand, Italy had the lowest incident population<\/li>\n<li><strong>Key Bronchopulmonary Dysplasia Companies:<\/strong> Oak Hill Bio, Advent Therapeutics Inc, Airway Therapeutics LLC, Ayuvis Research Inc, Chiesi Farmaceutici SpA, Insmed Inc, Laboratoire Aguettant SA, MediPost Co Ltd, Meridigen Biotech Co Ltd, Orphanix GmbH, Radikal Therapeutics Inc, Syntrix Biosystems Inc, Takeda Pharmaceutical Co Ltd, The Cell Factory BVBA, Trimunocor Ltd, United Therapeutics Corp, Windtree Therapeutics Inc, and others<\/li>\n<li><strong>Key Bronchopulmonary Dysplasia Therapies:<\/strong> OHB-607, CHF5633, PNEUMOSTEM, AT-100, Inhaled Nitric Oxide, Curosurf, Sildenafil, recombinant human CC10, OHB-607, and others<\/li>\n<li>The Bronchopulmonary Dysplasia epidemiology based on gender analyzed that severity\u2010specific data reveal the highest number of preterm infants have mild Bronchopulmonary Dysplasia<\/li>\n<li>The Bronchopulmonary Dysplasia market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchopulmonary Dysplasia pipeline products will significantly revolutionize the Bronchopulmonary Dysplasia market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Bronchopulmonary Dysplasia Market Report-&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchopulmonary-dysplasia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/bronchopulmonary-dysplasia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Bronchopulmonary Dysplasia Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Bronchopulmonary Dysplasia Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Bronchopulmonary Dysplasia market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Bronchopulmonary Dysplasia<\/li>\n<li>Prevalent Cases of Bronchopulmonary Dysplasia by severity<\/li>\n<li>Gender-specific Prevalence of Bronchopulmonary Dysplasia<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Bronchopulmonary Dysplasia<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Bronchopulmonary Dysplasia epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchopulmonary-dysplasia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Bronchopulmonary Dysplasia Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Bronchopulmonary Dysplasia Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchopulmonary Dysplasia market or expected to get launched during the study period. The analysis covers Bronchopulmonary Dysplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Bronchopulmonary Dysplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Bronchopulmonary Dysplasia Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>OHB-607:<\/strong> Oak Hill Bio\/Takeda<\/li>\n<li><strong>CHF5633:<\/strong> Chiesi Farmaceutici<\/li>\n<li><strong>PNEUMOSTEM:<\/strong> Medipost<\/li>\n<li><strong>AT-100:<\/strong> Airway Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Bronchopulmonary Dysplasia market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchopulmonary-dysplasia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Bronchopulmonary Dysplasia Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Bronchopulmonary Dysplasia Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Improved disease understanding<\/li>\n<li>Increase in Bronchopulmonary Dysplasia patient pool<\/li>\n<li>Biomarkers<\/li>\n<li>Limited late-stage drugs in the pipeline<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Bronchopulmonary Dysplasia Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The discrepancy in Epidemiology Data<\/li>\n<li>Lack of adequate clinical data<\/li>\n<li>High use of Non-pharmacological therapy<\/li>\n<li>Limitations in Animal Model<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Bronchopulmonary Dysplasia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Bronchopulmonary Dysplasia Companies:<\/strong> Oak Hill Bio, Advent Therapeutics Inc, Airway Therapeutics LLC, Ayuvis Research Inc, Chiesi Farmaceutici SpA, Insmed Inc, Laboratoire Aguettant SA, MediPost Co Ltd, Meridigen Biotech Co Ltd, Orphanix GmbH, Radikal Therapeutics Inc, Syntrix Biosystems Inc, Takeda Pharmaceutical Co Ltd, The Cell Factory BVBA, Trimunocor Ltd, United Therapeutics Corp, Windtree Therapeutics Inc, and others<\/li>\n<li><strong>Key Bronchopulmonary Dysplasia Therapies:<\/strong> OHB-607, CHF5633, PNEUMOSTEM, AT-100, Inhaled Nitric Oxide, Curosurf, Sildenafil, recombinant human CC10, OHB-607, and others<\/li>\n<li><strong>Bronchopulmonary Dysplasia Therapeutic Assessment:<\/strong> Bronchopulmonary Dysplasia current marketed and Bronchopulmonary Dysplasia emerging therapies<\/li>\n<li><strong>Bronchopulmonary Dysplasia Market Dynamics:<\/strong> Bronchopulmonary Dysplasia market drivers and Bronchopulmonary Dysplasia market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Bronchopulmonary Dysplasia Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Bronchopulmonary Dysplasia Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Bronchopulmonary Dysplasia companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bronchopulmonary-dysplasia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Bronchopulmonary Dysplasia Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Bronchopulmonary Dysplasia Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Bronchopulmonary Dysplasia<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Bronchopulmonary Dysplasia<\/p>\n<p style=\"text-align: justify;\">4. Bronchopulmonary Dysplasia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Bronchopulmonary Dysplasia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Bronchopulmonary Dysplasia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Bronchopulmonary Dysplasia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Bronchopulmonary Dysplasia&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Bronchopulmonary Dysplasia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Bronchopulmonary Dysplasia Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Bronchopulmonary Dysplasia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Bronchopulmonary Dysplasia Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Bronchopulmonary Dysplasia Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Bronchopulmonary Dysplasia Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Bronchopulmonary Dysplasia Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Bronchopulmonary Dysplasia Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Bronchopulmonary Dysplasia Appendix<\/p>\n<p style=\"text-align: justify;\">18. Bronchopulmonary Dysplasia Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bronchopulmonary-dysplasia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examine-delveinsight-key-companies-oak-hill-bio-advent-therapeutics-inc-airway-therapeutic\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bronchopulmonary-dysplasia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examine-delveinsight-key-companies-oak-hill-bio-advent-therapeutics-inc-airway-therapeutic\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cBronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Bronchopulmonary Dysplasia. DelveInsight&rsquo;s &ldquo;Bronchopulmonary Dysplasia Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an in-depth understanding of the Bronchopulmonary Dysplasia, historical and forecasted epidemiology &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bronchopulmonary-dysplasia-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examine-delveinsight-key-companies-oak-hill-bio-advent-therapeutics-inc-airway-therapeutic_649269.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-649269","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/649269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=649269"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/649269\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=649269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=649269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=649269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}